The co-CEOs of Amylyx Pharmaceuticals, Justin Klee and Josh Cohen, decided to remove their $380 million-generating ALS drug from the market after a study showed it wasn't beneficial for patients.
Amylyx stood by their commitment to integrity and following the science, offering the drug for free to patients who still opted to use it despite the findings.
Praised by ALS patients, critics, and experts, Amylyx's decision is seen as exemplary in an industry often scrutinized for prioritizing profits over patient well-being.
Experts like Holly Fernandez Lynch commended Amylyx for their actions but expressed concerns that such voluntary decisions aren't mandated, highlighting potential systemic issues in drug approval processes.
#drug-market-withdrawal #ethical-decision-making #als-treatment #pharmaceutical-industry #patient-centered-care
[
add
]
[
|
|
...
]